YKL-40/c-met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: A multi-institutional study

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Senetta, Rebecca ^a   Duregon, Eleonora ^a   Sonetto, Cristina ^b   Spadi, Rossella ^b   Mistrangelo, Massimiliano ^c   Racca, Patrizia ^b   Chiusa, Luigi ^a   Munoz, Fernando H ^a   Ricardi, Umberto ^a   Arezzo, Alberto ^c   Cassenti, Adele ^a   Castellano, Isabella ^a   Papotti, Mauro ^a   Morino, Mario ^c   Risio, Mauro ^d   Cassoni, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; MEMBRANE PROTEIN; OXALIPLATIN; PROTEIN YKL 40; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CHI3L1 PROTEIN, HUMAN; CHITINASE 3 LIKE PROTEIN 1; LECTIN; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; CLINICAL PROTOCOL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE FRACTIONATION; RECTUM CARCINOMA; SKIN TOXICITY; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR REGRESSION; ADENOCARCINOMA; BIOPSY; CLINICAL TRIAL; DRUG RESISTANCE; GAMMA RADIATION; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; RECTAL NEOPLASMS; THERAPEUTIC USE; VERY ELDERLY;

ADENOCARCINOMA; ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; CAPECITABINE; CHEMORADIOTHERAPY, ADJUVANT; CHITINASE-3-LIKE PROTEIN 1; DRUG RESISTANCE, NEOPLASM; FEMALE; GAMMA RAYS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LECTINS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECTAL NEOPLASMS;

EID: 84928816153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123759     Document Type: Article

References (63)

1. Frykholm GJ, Pahlman L, Glimelius B. Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys. 2001; 50: 427-434 PMID: 11380230
2. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355: 1114-1123 PMID: 16971718
3. Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008; 26: 3687-3694 doi: 10.1200/JCO.2007.15.3858 PMID: 18669453
4. Ricardi U, Racca P, Franco P, Munoz F, Fanchini L, Rondi N, et al. Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOX-ART). Med Oncol. 2013; 30: 581 doi: 10.1007/s12032-013-0581-0 PMID: 23606239
5. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999; 44: 1027-1038 PMID: 10421535
6. Medich D, McGinty J, Parda D, Karlovits S, Davis C, Caushaj P, et al. Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum. 2001; 44: 1123-1128 PMID: 11535851
7. Wheeler JM, Dodds E, Warren BF, Cunningham C, George BD, Jones AC, et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum. 2004; 47: 2025-2031 PMID: 15657650
8. Duldulao MP, Lee W, Streja L, Chu P, Li W, Chen Z, et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum. 2013; 56: 142-149 doi: 10.1097/DCR.0b013e31827541e2 PMID: 23303141
9. Grade M, Wolff HA, Gaedcke J, Ghadimi BM. The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch Surg. 2012; 397: 543-555 doi: 10.1007/s00423-012-0929-5 PMID: 22382702
10. Rodel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Günther K, et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol. 2002; 178: 426-435 PMID: 12240548
11. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol. 2006; 32: 55-64 PMID: 16324817
12. Lin AY, Wong WD, Shia J, Minsky BD, Temple LK, Guillem JG, et al. Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy. Int J Colorectal Dis. 2008; 23: 243-249 PMID: 18046561
13. Huh JW, Kim HR, Kim YJ. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum. 2013; 56: 698-703 doi: 10.1097/DCR.0b013e3182837e5b PMID: 23652742
14. Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, Park HW, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum. 2007; 50: 1342-1353 PMID: 17665260
15. Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol. 2005; 36: 364-371 PMID: 15891997
16. Watanabe T, Komuro Y, Kiyomatsu T, Kanazawa T, Kazama Y, Tanaka J, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res. 2006; 66: 3370-3374 PMID: 16585155
17. Jakob C, Liersch T, Meyer W, Becker H, Baretton GB, Aust DE. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol. 2008; 14: 1060-1066 PMID: 18286688
18. Akiyoshi T, Kobunai T, Watanabe T. Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today. 2012; 42: 713-719 doi: 10.1007/s00595-012-0223-8 PMID: 22706722
19. Moussata D, Amara S, Siddeek B, Decaussin M, Hehlgans S, Paul-Bellon R, et al. XIAP as a radioresistance factor and prognostic marker for radiotherapy in human rectal adenocarcinoma. Am J Pathol. 2012; 181: 1271-1278 doi: 10.1016/j.ajpath.2012.06.029 PMID: 22867709
20. Wang L, Zhang XM, Li Z, Liu XJ, Chai J, Zhang GY, et al. Overexpression of nuclear beta-catenin in rectal adenocarcinoma is associated with radioresistance. World J Gastroenterol. 2013; 19: 6876-6882 doi: 10.3748/wjg.v19.i40.6876 PMID: 24187464
21. Avoranta ST, Korkeila EA, Ristamaki RH, Syrjanen KJ, Carpen OM, Pyrhönen SO, et al. ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer. Hum Pathol. 2013; 44: 966-974 doi: 10.1016/j.humpath.2012.10.003 PMID: 23332924
22. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 2005; 23: 1826-1838 PMID: 15774776
23. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009; 74: 673-688 doi: 10.1016/j.ijrobp.2009.03.003 PMID: 19480968
24. Borst P, Wessels L. Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle. 2010; 9: 4836-4840 PMID: 21150277
25. Brettingham-Moore KH, Duong CP, Greenawalt DM, Heriot AG, Ellul J, Dow CA, et al. Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clin Cancer Res. 2011; 17: 3039-3047 doi: 10.1158/1078-0432.CCR-10-2915 PMID: 21224373
26. Casado E, Garcia VM, Sanchez JJ, Blanco M, Maurel J, Feliu J, et al. A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer. Clin Cancer Res. 2011; 17: 4145-4154 doi: 10.1158/1078-0432.CCR-10-2257 PMID: 21467161
27. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-337 doi: 10.1038/nature11252 PMID: 22810696
28. Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel). 2010; 2: 1453-1491 doi: 10.3390/cancers2031453 PMID: 24281168
29. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res. 2005; 11: 3326-3334 PMID: 15867231
30. De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011; 103: 645-661 doi: 10.1093/jnci/djr093 PMID: 21464397
31. Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 2011; 286: 15332-15343 doi: 10.1074/jbc.M110.212514 PMID: 21385870
32. Kawamura M, Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Hiro J, et al. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res. 2012; 32: 1527-1531 PMID: 22493396
33. Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 2013; 28: 9-18 doi: 10.1007/s00384-012-1520-9 PMID: 22733437
34. Shao R, Francescone R, Ngernyuang N, Bentley B, Taylor SL, Moral L, et al. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis. 2014; 35: 373-382 doi: 10.1093/carcin/bgt380 PMID: 24282289
35. Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011; 10: 742-751 doi: 10.1158/1535-7163.MCT-10-0868 PMID: 21357475
36. Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, et al. (2013) Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer. Clin Cancer Res 19: 710-720. doi: 10.1158/1078-0432.CCR-12-1703 PMID: 23243217
37. Yang H, Lee HW, Kim Y, Lee Y, Choi YS, Kim KH, et al. Radiosensitization of brain metastasis by targeting c-MET. Lab Invest. 2013; 93: 344-353 doi: 10.1038/labinvest.2012.180 PMID: 23381625
38. Chen HJ, Jiang YL, Lin CM, Tsai SC, Peng SF, Fushiya S, et al. Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells. Int J Oncol. 2013; 43: 141-150 doi: 10.3892/ijo.2013.1941 PMID: 23677180
39. Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol. 2013; 26: 302-313 doi: 10.1038/modpathol.2012.150 PMID: 22936063
40. Bhardwaj V, Cascone T, Cortez MA, Amini A, Evans J, Komaki RU, et al. Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer. 2013; 119: 1768-1775 doi: 10.1002/cncr.27965 PMID: 23423860
41. Gao W, Bing X, Li M, Yang Z, Li Y, Chen H. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma. Med Oncol. 2013; 30: 546 doi: 10.1007/s12032-013-0546-3 PMID: 23536000
42. An X, Wang F, Shao Q, Wang FH, Wang ZQ, Wang ZQ, et al. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. Cancer. 2014; 120: 675-682 PMID: 24804300
43. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994; 73: 2680-2686 PMID: 8194005
44. Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2009; 20: 298-304 doi: 10.1093/annonc/mdn635 PMID: 18836087
45. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002; 194: 131-135; discussion 135-136 PMID: 11848629
46. Rosenthal DI, Catalano PJ, Haller DG, Landry JC, Sigurdson ER, Spitz FR, et al. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. Int J Radiat Oncol Biol Phys. 2008; 72: 108-113 doi: 10.1016/j.ijrobp.2008.05.054 PMID: 18722265
47. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene. 2000; 19: 1547-1555 PMID: 10734314
48. Stella GM, Benvenuti S, Gramaglia D, Scarpa A, Tomezzoli A, Cassoni P, et al. MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat. 2011; 32: 44-50 doi: 10.1002/humu.21374 PMID: 20949619
49. Vigna E, Comoglio PM. Targeting the oncogenic Met receptor by antibodies and gene therapy. Oncogene. 2014. doi: 10.1038/onc.2014.142
50. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3: 347-361 PMID: 12726861
51. Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, et al. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis. PLoS One. 2014; 9: e84502 doi: 10.1371/journal.pone.0084502 PMID: 24416238
52. Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, et al. Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med. 2011; 15: 1999-2006 doi: 10.1111/j.1582-4934.2010.01122.x PMID: 20629992
53. Yu H, Li X, Sun S, Gao X, Zhou D. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. Biochem Biophys Res Commun. 2012; 427: 659-665 doi: 10.1016/j.bbrc.2012.09.117 PMID: 23026049
54. Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol. 2013; 4: 122 doi: 10.3389/fphys.2013.00122 PMID: 23755018
55. Kawada M, Seno H, Kanda K, Nakanishi Y, Akitake R, Komekado H, et al. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene. 2012; 31: 3111-3123 doi: 10.1038/onc.2011.498 PMID: 22056877
56. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol. 2011; 24: 1146-1155 doi: 10.1038/modpathol.2011.70 PMID: 21478826
57. Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures. PLoS One. 2014; 9: e99399 doi: 10.1371/journal.pone.0099399 PMID: 24922520
58. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer. 2002; 95: 267-274 PMID: 12124825
59. Abou-Bakr AA, Elbasmi A. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J Oncolog. 2013; 1: 28-34 PMID: 23996864
60. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002; 94: 1121-1130 PMID: 11920483
61. Hermanek P, Merkel S, Hohenberger W. Prognosis of rectal carcinoma after multimodal treatment: ypTNM classification and tumor regression grading are essential. Anticancer Res. 2013; 33: 559-566 PMID: 23393349
62. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014; 32: 1554-1562 doi: 10.1200/JCO.2013.54.3769 PMID: 24752056
63. Valentini V, Minsky BD. Tumor regression grading in rectal cancer: is it time to move forward? J Clin Oncol. 2014; 32: 1534-1536 doi: 10.1200/JCO.2014.55.4766 PMID: 24752055